Dupilumab Treatment in Children Aged 6-11 Years With Atopic Dermatitis: A Multicentre, Real-Life Study.

Maddalena NapolitanoGabriella FabbrociniIria NeriLuca StingeniValeria BoccalettiVincenzo PiccoloGiuseppe Fabrizio AmorusoGiovanna MalaraRocco De PasqualeEugenia Veronica Di BrizziLaura DiluvioLuca BianchiAndrea ChiricozziAdriana Di GuidaElisabetta Del DucaViviana MoscheseVito Di LerniaFederica DragoniMichaela GruberKatharina HanselAmelia LicariSara MantiSalvatore LeonardiLuca MastorinoMichela OrtoncelliEugenio ProvenzanoAntonino PalermoVincenzo PatellaTiziana PedutoElena PezzoloViviana PirasLuca PotestioTeresa BattistaRosanna SattaStefania TerminePaolo PalmaPaola ZangariCataldo Patruno

Published in: Paediatric drugs (2022)

Our real-life data seem to confirm the effectiveness of dupilumab in paediatric patients on all disease aspects, including extent and severity of signs, intensity of symptoms, sleep and QoL, with a good safety profile.

Keyphrases

atopic dermatitis
end stage renal disease
randomized controlled trial
chronic kidney disease
ejection fraction

newly diagnosed
intensive care unit
clinical trial
emergency department
young adults

prognostic factors
sleep quality
peritoneal dialysis
physical activity
electronic health record

study protocol
patient reported outcomes
depressive symptoms
deep learning